Megumi Hamano Nagaoka, Hiroshi Akiyama and Tamio Maitani*
National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya, Tokyo 158-8501, Japan
First published on 27th November 2003
Vanadium (V) is an essential metal for mammals. It has different valence states. In blood, V is bound to transferrin (Tf), a glycoprotein that has two metal-binding sites (C-lobe site and N-lobe site). In the present study, the binding patterns of V to serum Tf were analyzed by combined on-line HPLC and high-resolution ICP-MS (HPLC/HR-ICP-MS). The levels of 51V, 56Fe and 32S, which are interfered with polyatomic ions such as 35Cl16O+, 38Ar13C+ and 37Cl14N+, 40Ar16O+ and 40Ca16O+, and 16O2+, respectively, when using quadrupole ICP-MS, could be monitored simultaneously by HR-ICP-MS at a resolution of m/Δm = 4000. Sample (a 1 ml portion of serum from a healthy person or 2 mg of human serum Tf (hTf)) was directly subjected to HPLC equipped with an anion-exchange column. V in human serum without any in vitro V spike was detected as VC–Tf (V bound to C-lobe site of Tf) and metal2–Tf. Since V(III) was most favorable in terms of the binding to hTf in the presence of bicarbonate and V bound to the C-lobe site of hTf was detected only in the case of V(III) among the three valence states of V, it was suggested that a part, at least, of V in the VC–Tf in healthy human serum may be present as V(III), in addition to the generally accepted V(IV).
Transferrin (Tf) is a glycoprotein of about 80 kDa with the characteristic property of requiring a synergistic anion.7 Although its principal role in the blood is to transfer iron (Fe) to cells,8 it can bind a large number of other metals. Vanadium is bound to Tf in the blood.9,10 It has two homologous lobes for metal-binding (hereafter called the N-lobe site and the C-lobe site) connected by a single short peptide.11 Although the amino acid sequence of the two lobes reveals extensive identity12 and the ligands for each Fe-binding site consist of two tyrosines, one histidine, one aspartic acid and a bidentate anion such as carbonate,1 the binding affinity of the two lobes is not identical.13,14 The preferential site depends on the kinds of Tf, metal and synergistic anion.15 For example, we reported the preferential binding of Fe and aluminium (Al) to the N-lobe site in the presence of bicarbonate as the synergistic anion.16,17
Vanadium ions are present in several valence states including V(III) (vanadic), V(IV) (vanadyl) and V(V) (vanadate). Since V(IV) and V(V) ions are present as oxovanadium ions (VO2+ and VO2+, respectively), they are bulky. Moreover, the oxo group(s) of oxovanadium ions may supply ligands supplied usually by synergistic anions.18 The fact that V(V) binding to Tf does not require the presence of bicarbonate19,20 may support this explanation, although the synergistic anion is required for the binding of V(IV) to Tf.21,22 Thus, the preferential binding lobe and the binding affinity of V ion to Tf differ markedly depending on its valence state.
An on-line combination of HPLC and metal-detection spectrometry is widely used for the speciation of metals in biological samples. For detecting metals, ICP-MS has an extremely high sensitivity,23 which is preferable for trace metals in biological samples. However, polyatomic-isotope interference from argon gas, atmospheric gas and biological materials can cause serious errors in the determination with common quadrupole ICP-MS instruments.24 In the case of V in biological samples, 35Cl16O+ (m/z 50.964 u), 38Ar13C+ (m/z 50.966 u) and 37Cl14N+ (m/z 50.969 u) interfere with the detection of 51V (m/z 50.944 u and the natural abundance is 99.75%). Moreover, in the measurement of Fe, which is essential for the study of Tf, the detection of 56Fe (m/z 55.935 u and natural abundance is 91.72%) is affected by 40Ar16O+ (m/z 55.957 u), because an argon plasma is used in the ICP spectrometry. However, by using a double focusing high-resolution ICP-MS (HR-ICP-MS), the analyte signal is separated from the interference.25
In our previous study, the binding of V ions to two lobes of apo-human serum Tf (hTf) in the presence and absence of bicarbonate was studied in three different valence states (V(III), V(IV) and V(V)), using an on-line combination of HPLC and HR-ICP-MS (HPLC/HR-ICP-MS) with an anion-exchange column.26 The three ions ranked V(III) > V(IV) > V(V) in affinity to hTf in the presence of bicarbonate.
In the present study, we studied the binding patterns of both V and Fe in healthy human serum. Since the V level was quite low, a 1 ml sample was required to obtain the V peak even with HR-ICP-MS. The established new analytical system and the new finding on the valence state of V in the serum are reported in the present study.
Apo-hTf was dissolved in 10 mM Tris–HCl (pH 7.4) containing 25 mM NaHCO3 as the synergistic anion. Each solution was added to the apo-hTf solution (2 mg apo-hTf ml−1) and the mixture was allowed to stand for the indicated times. After preparing each reagent solution, all tubes and bottles were sealed under a nitrogen gas atmosphere.
HPLC condition 1 for column 1 | ||
---|---|---|
Time/min | B (%) | Flow/ml min−1 |
0–0.1 | 0–8 | 1 |
0.1–8 | 8 | 1 |
8–22 | 8–18 | 1 |
22–35 | 18 | 1 |
HPLC condition 2 for column 2 | ||
---|---|---|
Time/min | B (%) | Flow/ml min−1 |
0–2 | 0 | 0.7 |
2–3 | 0 | 0.7–1 |
4–7 | 0–7 | 1 |
7–19 | 7 | 1 |
19–20 | 7 | 1–3 |
20–28 | 7 | 3 |
28–33 | 7–9 | 3 |
33–36 | 9–14 | 3 |
37–38 | 14 | 3–1 |
38–95 | 14 | 1 |
HR-ICP-MS data acquisition parameters are as follows: E-scan, mass window, 100%; search window, 60%; integration window, 60%; acquisition time, 2.22 s per each run.
![]() | ||
Fig. 1 HPLC-UV (280 nm, top) (a) and HPLC/HR-ICP-MS (32S (top), 56Fe (middle) and 51V (bottom) levels) (b) chromatograms for serum from a healthy person before (left) and after (right) the addition of VCl3. The respective sample solutions were sealed under a nitrogen gas atmosphere and allowed to stand for 2 h before analysis. Column 1 and HPLC condition 1 were used. |
However, the heights of V peaks in the serum sample were different from those in the hTf sample of our previous report. Namely, V peaks ranked metal2–Tf > VC–Tf > VN–hTf for the serum sample in Fig. 1 (right panel) and ranked metal2–hTf > VN–hTf > VC–hTf for the hTf sample. Therefore, it was considered that various compounds in serum such as citrate, oxalate, etc. may have affected the binding affinity of V to Tf in the serum sample. In fact, though citrate is a non-synergistic anion, it is present in serum at the concentration of 0.1 mM and forms chelates easily with V(III).
In our previous study,17 beside the FeC–hTf peak at 16 min, a small Fe peak was observed at 10 min and it was ascribed to Fe bound to hTf with smaller numbers of sialic acid molecules, as sialidase-treated hTf eluted faster than non-treated hTf.27 Therefore, in establishing HPLC condition 2, it was ensured that FeC–hTf could be distinguished from Fe bound to disialo- or trisialo-hTf. Thus, the HPLC condition 2 was prudently established to perfectly separate the peaks of V bound to native-hTf and that of V bound to disialo- or trisialo-hTf.
Since the 1 ml portion of the sample, which is ten times that used with column 1 in Fig. 1, was analyzed, the levels of 34S (m/z 33.968, natural abundance 4.21%) and 54Fe (m/z 53.940, natural abundance 5.80%) were monitored instead of 32S (m/z 31.972, natural abundance 95.02%) and 56Fe (m/z 55.935, natural abundance 91.72%), respectively. The eluate from 0 to 38 min was rich in ionic and organic compounds and so the flow rate under HPLC condition 2 was frequently changed. The HPLC apparatus was thus not combined with the HR-ICP-MS instrument until 38 min to avoid damage to the HR-ICP-MS instrument. Hence, the chromatograms started at 38 min in Fig. 2.
![]() | ||
Fig. 2 HPLC/HR-ICP-MS (34S and 54Fe levels) chromatograms for apo-hTf solution (a) and apo-hTf solution supplemented with Fe-citrate (1:1) (Fe/hTf molar ratio = 1) (b) in the presence of bicarbonate. The mixed solution was allowed to stand for 24 h. Column 2 and HPLC condition 2 were used. |
![]() | ||
Fig. 3 HPLC-UV (280 nm, top) (a) and HPLC/HR-ICP-MS (32S (top), 56Fe (middle) and 51V (bottom) levels) (b) chromatograms for serum from a healthy person without any V spike. Column 2 and HPLC condition 2 were used. |
The V concentration in the serum sample was measured with a 20 fold diluted sample. The V concentration in the serum was 140 pg ml−1. The total area of V from 38 to 95 min corresponded to about 60% of the injected V content. The peak area of VC–Tf peak occupied 42% of the total V area. Therefore, it was considered that most of the total V in the serum was detected by HPLC/HR-ICP-MS. The reported serum V concentrations were 50 pg ml−1 from electrothermal atomic absorption spectrometry,28 and 31 pg ml−1 from radiochemical neutron activation analysis29 and reported to be 10–760 pg ml−1 with HR-ICP-MS.30 The serum V concentration in the present study (140 pg ml−1) was comparable with the reported values.
![]() | ||
Fig. 4 HPLC/HR-ICP-MS (34S, 54Fe and 51V levels) chromatograms for serum from a healthy person without any V spike (a), serum spiked with VCl3 (b) or VOSO4 (c) at 25 µM. The mixed solution was allowed to stand for 2 h. Column 2 and HPLC condition 2 were used. |
In Fig. 4 (top), two obvious V peaks were observed at the retention times of VC–Tf (53 min) and metal2–Tf (59 min) in the chromatogram for serum without any V spike. In the previous study, the N-lobe site was the preferential binding site of Fe in the presence of bicarbonate.16 On the other hand, V(III) preferred both the C-lobe and N-lobe as affirmed by the Urea–PAGE.26 Therefore, it seems plausible that V(III) binds to the C-lobe in serum and metal2–Tf is VC,FeN–Tf.
When the serum was supplemented with V(III) at the molar ratio (V/Tf) of 1, two major peaks were observed at the same retention times of FeC–Tf (53 min) and metal2–Tf (59 min). On the other hand, V(IV) gave a peak at a slightly longer retention time (55 min) as well as the peak of N-lobe in an “open form”26 at the retention time of 71 min. The observed slightly longer retention time (55 min) may suggest that when bound to the C-lobe site, bulky V(VI) (VO2+) is bound to Tf in an “open form” as also observed in the previous study26.
In the previous study,26 VC–hTf in the “closed form” corresponding to the peak at 53 min in this study could not be detected by the HPLC/HR-ICP-MS after the addition of V(IV) or V(V) ion to apo-hTf in the presence of bicarbonate. Moreover, a part of the V ions was removed from V–hTf during the column procedure.26 It was also reported that V(V)–hTf binding was dissociated during the elution in the anion-exchange column procedure.31 Therefore, the possibility that the V bound to the C-lobe site of Tf in the serum detected by the HPLC/HR-ICP-MS is V(IV) and/or V(V) seems low.
Consequently, it was considered that the V detected as VC–Tf in the “closed form” was V(III). Thus, the interpretation that the V peak detected in the serum from a healthy person is of V(III) bound to the C-lobe site was confirmed by the standard addition experiment. This is the first report that demonstrates the V-binding lobe of Tf in healthy human serum.
Recently, it has been demonstrated that V compounds show insulin-like activity.3–6 The effectiveness of V(IV) and V(V) compounds has been reported previously.32 Since V(III) has a much higher affinity for hTf, the possibility that V ions are transferred in serum as V(III) may have to be studied further to clarify the action of V in the body.
This journal is © The Royal Society of Chemistry 2004 |